CLINICAL PROTOCOL 
Product: VCL-1102 
July 7, 1994 
VICAL INC. 
9373 Towne Centre Dr., Ste. 100 
San Diego, CA 92121 
7.2 Chest X-ray. 
7.3 EKG. 
7.4 CBC, platelet count, differential, PT, PTT. 
7.5 Blood chemistries: creatinine, BUN, bilirubin, alkaline phosphatase, LDH, SGOT, 
SGPT, phosphorus, uric acid, calcium, total protein, albumin, glucose. 
7.6 Lymphocyte Proliferative Response to PHA. 
7.7 Merieux multitest skin tests. 
7.8 Pregnancy test for women. 
7.9 HIV antibody test. 
7.10 Hepatitis screen. 
7.11 IL-2 antibody test. 
7.12 Tumor biopsies. 
7.13 CT/MRI/ Ultrasound (if relevant) for baseline and to evaluate status of 
disease. 
7.14 Special Tests: Blood will be drawn for serum to be analyzed by PCR for the 
presence of the plasmid. 
7.15 Blood draws during this study will be limited to a maximum of 60 mL each 
time. 
8.0 ADVERSE EVENTS AND REMOVAL FROM STUDY 
8.1 Patients will be monitored and questioned at every visit (see Schedule of Events, 
Appendix I) regarding the occurrence and nature of any adverse experiences. 
An event is any change in the physiological or psychological state other than the 
primary condition that qualifies the patient for this study. 
8.2 The Investigator must report to Ms. Susan Stahl (ph 619-453-9900, ext. 116, 
available 24 hours.) upon occurrence of any life-threatening events (Grade IV) 
that may be attributable to administration of the study drug, all fatal events, or 
Recombinant DNA Research, Volume 20 
[611] 
